Navigation Links
Perrigo Announces Approval for Rx Cetirizine Syrup
Date:6/19/2008

ALLEGAN, Mich., June 19 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Cetirizine Hydrochloride Syrup (Rx only), 1mg/mL. The product is comparable to McNeil Consumer Healthcare's Zyrtec(R) Syrup, 1mg/mL, indicated for the relief of symptoms associated with seasonal allergic rhinitis.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This approval reflects both our strategy to be first to market with important products and the unique position of the Company both in front of and behind the pharmacy counter. This product will join our line of Cetirizine tablets, Cetirizine D and Cetirizine OTC syrup. Additionally, it contains active ingredient supplied by our own API business, a continuation of our vertical integration efforts. This is yet another example of how we are making quality healthcare more affordable for consumers."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2007, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Confirms Filing for Generic Version of VANOS(R)
2. Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech
3. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
4. Perrigo Reports Record Sales and Earnings for Third Quarter Fiscal 2008
5. Perrigo Company Announces Quarterly Dividend
6. Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
7. Perrigo Company Will Release Third Quarter Fiscal 2008 Results on May 6, 2008
8. Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack
9. Perrigo Company to Present at the 12th Annual Sidoti Emerging Growth Institutional Investor Forum
10. Perrigo Company Announces Launch of Clobetasol Propionate Foam
11. Perrigo Company Receives Final Approval on Clobetasol Propionate Foam
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... the Affordable Care Act. Dr. Botelho advocates for the mass media launching of ... gives people ongoing opportunities to share their unfortunate experiences; such a movement can ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... services from offices headquartered in Jefferson County, is announcing the launch of a ... Birmingham. , The number of homeless women and children in Birmingham has grown ...
(Date:12/8/2016)... ... 08, 2016 , ... Coffey Agencies, a locally owned and ... in the northern Alabama and Georgia regions, is embarking on a charity drive ... has built a network of support and education facilities to develop and provide ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, MHA ... most comprehensive mental health systems reform legislation in more than fifty years. We ... the commitment of our elected officials to improving mental health services and supports ...
(Date:12/7/2016)... LAKE CITY, UTAH (PRWEB) , ... December 07, ... ... productivity, today announced the release of Smart Device Remote Control through a new ... management across all platforms and strengthens its mobile solutions to help businesses maximize ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  A new study ... that the use of opioid therapy to treat chronic ... the likelihood of more harmful consequences, including death. ... M.D., and Zankhana Mehta , M.D., authored the ... on chronic opioid therapy. The study was published in ...
(Date:12/8/2016)... CAMBRIDGE, Mass. , Dec. 8, 2016 /PRNewswire/ ... that it has obtained proof-of-mechanism for neflamapimod (previously ... recently completed Phase 2a clinical trials that demonstrated ... from Study 302 (12-week treatment) and Study 303 ... the Clinical Trials in Alzheimer,s Disease (CTAD) scientific ...
(Date:12/8/2016)... 2016 Mederi Therapeutics Inc . hat die behördliche Zulassung ... für gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast ... of Endoscopy at Wuhan Union Hospital ...
Breaking Medicine Technology: